Mesenchymal Stem/Stromal Cell (MSC) Exosome Ointment is under clinical development by Paracrine Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mesenchymal Stem/Stromal Cell (MSC) Exosome Ointment’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesenchymal Stem/Stromal Cell (MSC) Exosome Ointment overview
Cell therapy under development for the treatment of psoriasis. The therapeutic candidate consists of mesenchymal stem/stromal cell (MSC) exosomes and is administered topically in form of ointment.
Paracrine Therapeutics overview
Paracrine Therapeutics is a biopharma company focused on development of stem exosome for regenerative medicine. Paracrine Therapeutics is headquartered in Singapore City, Singapore.
For a complete picture of Mesenchymal Stem/Stromal Cell (MSC) Exosome Ointment’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
